Problem Solving: What’s the Best Approach?

June 20, 2016

Those of you in the pharmaceutical, biotech and medical device industries who encounter process and product problems on a regular basis, you likely grimace when one lands in your lap. There is a degree of dread associated with a problem solving requirement as it represents a diversion from other pressing matters and will require effort you hadn't necessarily budgeted for yourself. Indeed, effective problem solving takes time and attention; but that's generally a small investment compared to the impact and ramifications of a serious problem not solved.

So, the reality being what it is, what is the best approach to problem solving? That's a rhetorical question for sure as there's not a one-size-fits-all answer; however, one can form a foundation of problem solving skills and techniques that can be tweaked to fit the specific nature of the problem at hand.

The table below lists the step-by-step approaches used in 3 different disciplines: Six-Sigma, CAPA and Risk Management. Although terminology differs slightly, notice how very similar each discipline utilizes essentially the same problem solving approach: problem identification (Houston, we have a problem!), evaluation (how bad is the problem?), investigation (what caused the problem?), resolution (how do we fix the problem?), improve (what's the plan for fixing the problem?), and verification of the effectiveness of the implemented remediation plan (did we truly fix the problem?).

As mentioned, there is not a universally accepted problem solving approach, especially one that will guarantee the problem will be solved effectively every time. However, one could do worse by not using the industry accepted, best-practice approaches used by those who are six-sigma, CAPA and Risk Management experts.


Learn more about ProPharma's Compliance services. Contact us to get in touch with our subject matter experts for a customized presentation.

TAGS:

Several pills sitting on a table.

FDA publishes product-specific guidances to facilitate generic drug development

Today, FDA published a new batch of product-specific guidances (PSGs). PSGs provide recommendations for developing generic drugs and generating the evidence needed to support abbreviated new drug...

June 16, 2015

FDA Issues Final Guidance on Providing Regulatory Submission in Electronic Format – The eCTD Mandate is Coming

On May 5, 2015, the Food and Drug Administration (FDA) released the final guidance on Providing Regulatory Submissions in electronic format. The guidance implements the electronic submission...

FDA Solicits Feedback on ANDA Submissions – Amendments to ANDAs Under GDUFA Guidance, Appendix A

Ahead of this year’s reauthorization of the Generic Drug User Fee Amendments (GDUFA), FDA has established a docket to solicit comments on the content of Appendix A in the July 2018 guidance for...